As of November 6, 2026, Verrica Pharmaceuticals Inc. is a publicly traded company (Nasdaq: VRCA). The largest holder reporting an active stake on Schedule 13D is Paul B Manning, at 49.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Affinity Asset Advisors, LLC (5.5%) (Schedule 13D/A, November 28, 2025).
Is this your company?
About to sign with, pay or invest in Verrica Pharmaceuticals Inc.? See the free Snapshot first.
Free to see. No signup.
Is Verrica Pharmaceuticals Inc. a real, registered company?
- Verrica Pharmaceuticals Inc. files with the SEC under CIK 1660334 (its SEC filings).
- Its shares are listed under the ticker VRCA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in West Chester, Pennsylvania, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Verrica Pharmaceuticals Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Affinity Asset Advisors, LLC (filed 2026-01-29).
Who are Verrica Pharmaceuticals Inc.'s owners and officers?
Verrica Pharmaceuticals Inc.: incorporated in Delaware; business address in West Chester, Pennsylvania; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-02-17).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-12-10)
- : Executive Officer (Form D, 2025-12-10)
- : Executive Officer (Form D, 2025-12-10)
- : Executive Officer (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-02-17 | Armistice Capital, LLC | 4.99% |
| Schedule 13G/A, 2026-01-29 | Affinity Asset Advisors, LLC | 5.5% |
| Schedule 13D/A, 2025-12-30 | Caligan Partners LP | 9.99% |
| Schedule 13G, 2025-12-03 | Affinity Asset Advisors, LLC | 5.47% |
| Schedule 13D/A, 2025-11-28 | Paul B Manning | 49.9% |
| Schedule 13D, 2025-11-24 | Caligan Partners LP | 9.99% |
| Schedule 13G/A, 2025-11-14 | Armistice Capital, LLC | 6.77% |
| Schedule 13G/A, 2025-08-14 | Armistice Capital, LLC | 9.99% |
Questions about who owns Verrica Pharmaceuticals Inc.
Who owns Verrica Pharmaceuticals Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Verrica Pharmaceuticals Inc.: Paul B Manning (49.9%, Schedule 13D/A, filed 2025-11-28), Caligan Partners LP (9.99%, Schedule 13D/A, filed 2025-12-30) and Affinity Asset Advisors, LLC (5.5%, Schedule 13G/A, filed 2026-01-29).
Who are the largest shareholders of Verrica Pharmaceuticals Inc.?
By the share each holder's latest filing reports, the largest holders of Verrica Pharmaceuticals Inc. on this page are Paul B Manning (49.9%), Caligan Partners LP (9.99%) and Affinity Asset Advisors, LLC (5.5%).
When did Paul B Manning buy into Verrica Pharmaceuticals Inc.?
The filings give report dates, not purchase dates. The earliest filing from Paul B Manning on this page is the Schedule 13D/A, filed 2025-11-28, reporting 49.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Verrica Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Verrica Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Verrica Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Verrica Pharmaceuticals Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director and 10% owner: 7,638,994 shares (44.5% of shares outstanding), 3,958,189 held directly and 3,680,805 indirectly (Form 4, 2025-11-25).
- BKB Growth Investments, LLC, a 10% owner: 3,348,372 shares (19.5% of shares outstanding) (Form 3, 2026-01-26).
- , a director: 1,873,800 shares (10.9% of shares outstanding) (Form 4, 2024-11-26).
- Johnson David Edward: 923,910 shares (5.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 3, 2025-12-30).
- Caligan Partners LP: 923,910 shares (5.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 3, 2025-12-30).
Shares outstanding: 17,178,786 as of 2026-07-31, from the company's latest SEC cover page.
How much has Verrica Pharmaceuticals Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-12-10 | $50.02M | $50.02M |
Keep reading
More on Verrica Pharmaceuticals Inc. and the records around it.
Verrica Pharmaceuticals Inc. elsewhere on the record
- 5%+ stake filings Feb 2026
- Form D filing Dec 2025
Companies that share a holder
- Paul B Manning also filed stake reports on 2 other companies: LIQUIDIA CORP (Aug 2026), CANDEL THERAPEUTICS, INC. (Mar 2026)
- Caligan Partners LP also filed stake reports on 9 other companies: Avalo Therapeutics, Inc. (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026)
- Affinity Asset Advisors, LLC also filed stake reports on 13 other companies: Amanat Acquisition Corp. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Equillium Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/verrica-pharmaceuticals